Influenza virosomes: a flu jab for malaria?

Trends in Parasitology

Volumn 24, Issue 9, 2008, Pages 382-385

  Cavanagh, David R ^a   Remarque, Edmond J ^b   Sauerwein, Robert W ^c   Hermsen, Cornelus C ^c   Luty, Adrian J F ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; ASPARAGINYLALANYLASPARAGINYLPROLINE; CIRCUMSPOROZOITE PROTEIN; HEPATITIS B VACCINE; IMMUNOPOTENTIATING RECONSTITUTED INFLUENZA VIROSOME; INFLUENZA VIROSOME; MALARIA VACCINE; MEASLES VACCINE; MULTIEPITOPE THROMBOSPONDIN RELATED ADHESION PROTEIN VACCINE; PARASITE ANTIBODY; PEV 301; PEV 302; PEV3A VACCINE; RECOMBINANT PROTEIN; SIMIAN ADENOVIRUS VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIROSOME VACCINE;

ADENOVIRUS; ALPHA VIRUS; ANTIBACTERIAL ACTIVITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIPROTOZOAL ACTIVITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEVELOPMENTAL STAGE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IMMUNOPOTENTIATION; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; MALARIA; MONOTHERAPY; NONHUMAN; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PROTEIN VARIANT; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; VIRAL GENE THERAPY; YELLOW FEVER FLAVIVIRUS;

ANTIGEN PRESENTATION; DRUG DELIVERY SYSTEMS; HUMANS; INFLUENZA A VIRUS; MALARIA VACCINES; VACCINES, VIROSOME;

PLASMODIUM FALCIPARUM;

EID: 49449099166     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2008.06.002     Document Type: Short Survey

References (20)

1. Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine 21 (2003) 921-924
2. Okitsu S.L., et al. Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chem. Biol. 14 (2007) 577-587
3. Thompson F.M., et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a Phase IIa clinical trial. PLoS ONE 3 (2008) e1493
4. Genton B., et al. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PloS ONE 2 (2007) e1018
5. Okitsu S.L., et al. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PloS ONE 2 (2007) e1278
6. McConkey S.J., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9 (2003) 729-735
7. Heppner D.G., et al. The dog that did not bark: malaria vaccines without antibodies. Trends Parasitol. 23 (2007) 293-296
8. Webster D.P., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4836-4841
9. Hermsen C.C., et al. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am. J. Trop. Med. Hyg. 71 (2004) 196-201
10. Davenport F.M., et al. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J. Exp. Med. 98 (1953) 641-656
11. Fattom A., et al. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 17 (1999) 126-133
12. Kocken C.H., et al. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect. Immun. 70 (2002) 4471-4476
13. Mueller M.S., et al. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect. Immun. 71 (2003) 4749-4758
14. Krzych U., and Schwenk R. The dissection of CD8 T cells during liver-stage infection. Curr. Top. Microbiol. Immunol. 297 (2005) 1-24
15. Ophorst O.J., et al. Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine 25 (2007) 6501-6510
16. Vekemans J., and Ballou W.R. Plasmodium falciparum malaria vaccines in development. Expert Rev. Vaccines 7 (2008) 223-240
17. Bejon P., et al. Phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin. Trials 1 (2006) e29
18. Reyes-Sandoval A., et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur. J. Immunol. 38 (2008) 732-741
19. Weiss W.R., et al. Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS ONE 2 (2007) e1063
20. Li S., et al. Viral vectors for malaria vaccine development. Vaccine 25 (2007) 2567-2574